| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cantor Fitzgerald analyst Prakhar Agrawal upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from Neutral to Overweight.
Citizens analyst Jonathan Wolleben maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market Outperform and raises the ...
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(5.08) per share which missed the analyst consensus estima...
B of A Securities analyst Alexandria Hammond upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from Underperform to Neutral an...
Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis ...
Piper Sandler analyst Yasmeen Rahimi maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and raises the price...